Sponsor Pipeline

Eikon Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
5
Recruiting
2
Phase 3
6
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-07 NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy…		 Trial sites expanded: 10 -> 14 locations
Active Trials by Phase
Phase 2/3
2
Phase 2
1
Phase 1/2
3
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT06697301 Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as… Advanced Melanoma Recruiting
NCT07365319 A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy… Non Small Cell Lung Cancer (Squamous or Non Squamous) Recruiting
Phase 2
NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With… NSCLC Active, Not Recruiting
Phase 1/2
NCT06907043 A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced… Advanced Solid Tumors Recruiting
NCT07262619 EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor… Advanced Solid Tumors Recruiting
NCT06253130 A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With… Advanced Solid Tumor Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Melanoma (1) Colorectal Cancer (1) Gastric Cancer (1) Endometrial Cancer (1) Lung Cancer (1)
Get alerts when Eikon Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free